Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
NovoCure Limited - Ordinary Shares
(NQ:
NVCR
)
30.57
-1.32 (-4.15%)
Streaming Delayed Price
Updated: 1:42 PM EST, Dec 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NovoCure Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
December 02, 2024
From
Zai Lab
Via
Business Wire
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
December 02, 2024
From
Novocure
Via
Business Wire
Novocure to Participate in Upcoming Investor Conferences
November 27, 2024
From
Novocure
Via
Business Wire
NovoCure Ltd. (NASDAQ: NVCR) Leading the Way in Thursday Trading Based on Percentage Gain
January 18, 2024
Via
Investor Brand Network
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
November 21, 2024
From
Novocure
Via
Business Wire
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
November 21, 2024
From
Novocure
Via
Business Wire
Novocure Appoints Christoph Brackmann as Chief Financial Officer
October 30, 2024
From
Novocure
Via
Business Wire
Novocure Reports Third Quarter 2024 Financial Results
October 30, 2024
From
Novocure
Via
Business Wire
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
October 15, 2024
From
Novocure
Via
Business Wire
Novocure to Report Third Quarter 2024 Financial Results
October 01, 2024
From
Novocure
Via
Business Wire
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
September 09, 2024
From
Novocure
Via
Business Wire
Novocure Announces Planned CEO Transition
September 03, 2024
From
Novocure
Via
Business Wire
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
August 28, 2024
From
Novocure
Via
Business Wire
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
August 14, 2024
From
Novocure
Via
Business Wire
Novocure Reports Second Quarter 2024 Financial Results
July 25, 2024
From
Novocure
Via
Business Wire
Novocure to Report Second Quarter 2024 Financial Results
July 01, 2024
From
Novocure
Via
Business Wire
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
June 03, 2024
From
Novocure
Via
Business Wire
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
May 02, 2024
From
Novocure
Via
Business Wire
Novocure Reports First Quarter 2024 Financial Results
May 02, 2024
From
Novocure
Via
Business Wire
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
April 24, 2024
From
Novocure
Via
Business Wire
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
April 05, 2024
From
Novocure
Via
Business Wire
Novocure to Report First Quarter 2024 Financial Results
April 01, 2024
From
Novocure
Via
Business Wire
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
March 27, 2024
From
Novocure
Via
Business Wire
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
March 11, 2024
From
Novocure
Via
Business Wire
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
February 22, 2024
From
Novocure
Via
Business Wire
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
January 18, 2024
From
Novocure
Via
Business Wire
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
January 09, 2024
From
Novocure
Via
Business Wire
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
January 08, 2024
From
Novocure
Via
Business Wire
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
January 04, 2024
From
Novocure
Via
Business Wire
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Novocure
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.